NCT02944968CompletedNot Applicable
Clinical Study for Workflow and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System (the THERMOCOOL SMARTTOUCH® SF-5D Catheter With Temperature Sensing Capabilities and Micro Electrodes and CARTO 3 V 6.0 Technology) in Treatment of Patients With Paroxysmal Atrial Fibrillation (QDOT-Micro)
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Biosense Webster, Inc.
- Enrollment
- 51
- Primary Endpoint
- Number of Participants With Entrance Block Confirmation in the Total Effectiveness Outcome Population
Study Overview
Brief Summary
The QDOT-Micro study is a prospective, multi-center, non-randomized, interventional clinical study.
Detailed Description
The purpose of this study is to evaluate the workflow and acute performance , during standard electrophysiology mapping and RF ablation procedures, of the THERMOCOOL SMARTTOUCH® SF-5D catheter with temperature sensing capabilities and micro electrodes used in combination with the CARTO® 3 Navigation System with THERMOCOOL SMARTTOUCH® SF-5D-module.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Candidates for this study must meet ALL of the following criteria:
- •Age 18 or older
- •Patients who have signed the Patient Informed Consent Form (ICF)
- •Subjects diagnosed with symptomatic documented PAF* who are candidates for catheter ablation
- •Able and willing to comply with all pre-, post-, and follow-up testing and requirements (eg. Patient not confined by a court ruling)
Exclusion Criteria
- •Candidates for this study will be EXCLUDED from the study if ANY of the following conditions apply:
- •Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- •Previous ablation for atrial fibrillation.
- •Previously diagnosed with persistent AF.
- •Documented Left Atrial thrombus
- •Any carotid stenting or endarterectomy
- •LA size >50mm
- •Uncontrolled heart failure or NYHA function class III and IV
- •History of blood clotting or bleeding abnormalities or contraindication to anticoagulation ( heparin, warfarin, or dabigatran)
- •History of a documented thromboembolic event (including TIA) within the past 12 months.
- •Previous PCI/MI within the past 3 months
- •Previous cardiac surgery (e.g CABG) in conjunction with valve surgery or any valvular cardiac surgical/percutaneous procedure (e.g ventriculotomy, atriomy, valve repair or replacement, presence of a prosthetic valve) within the past 6 months.
- •Awaiting cardiac transplantation or other cardiac surgery within the next 6 months.
- •Unstable angina
- •Significant pulmonary disease (eg, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
- •Acute illness, active systemic infection, or sepsis.
- •Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation.
- •Presence of a condition that precludes vascular access.
- •Presence of implantable cardioverter-defibrillator (ICD)
- •Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this trial.
- •Currently enrolled in an investigational study evaluating another device, biologics, or drug.
- •Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the clinical investigation (as evidenced by pregnancy test if of child bearing potential).
- •Life expectancy less than 12 months.
- •Presenting contra-indication for the devices used in the study, as indicated in the respective instructions for use.
Arms & Interventions
Treatment group
Experimental
Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
Intervention: THERMOCOOL SMARTTOUCH® SF-5D catheter (Device)
Outcomes
Primary Outcomes
Number of Participants With Entrance Block Confirmation in the Total Effectiveness Outcome Population
Time Frame: Day of ablation procedure
Confirmation of entrance block in all targeted PVs after adenosine and/or isoproterenol challenge achieved at the end of procedure. If the challenge was not done, confirmation data would not be available.
Secondary Outcomes
- Number of Participants With Early Onset Primary Adverse Events in Total Safety Population(Seven Days Post Procedure)
Investigators
Similar Trials
Completed
Not Applicable
Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation.Paroxysmal Atrial FibrillationNCT03459196Biosense Webster, Inc.54
Completed
Not Applicable
Mid-Q Response StudyHeart Failure NYHA Class IIILeft Bundle-Branch BlockHeart Failure NYHA Class IIHeart Failure With Reduced Ejection Fraction (HFrEF)Heart Failure NYHA Class IVHeart FailureNCT04180696Medtronic Cardiac Rhythm and Heart Failure177
Recruiting
Not Applicable
A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer DetectionWomen's Health: Neoplasm of BreastNCT06291896Umbria Bioengineering Technologies10,000
Unknown
Not Applicable
MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal CancerMulti-disciplinary TreatmentNCT03400657Peking University484
Completed
Not Applicable
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in GreeceAdvanced Soft Tissue SarcomaNCT02618122Genesis Pharma S.A.63